A Strategy to Reduce Red Marrow Dose for Intraperitoneal Radioimmunotherapy

Daniel J. Macey and R. F. Meredith
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35233

Abstract

The aim of this study was to determine whether shorter-lived radionuclides can reduce red marrow (RM) toxicity for i.p. radioimmunotherapy (RIT). The potential radionuclides, which included Lu-177, I-131, Y-90, Re-186, Re-188, and Ho-166, were attached to antibody CC49. Each radiopharmaceutical was assumed to have identical in vivo pharmacokinetics. Blood and whole body retention data acquired from 26 patients who received i.p. RIT with Lu-177 CC49 were used as input. The average biological half-time of Lu-177 CC49 in the whole body was 280 h, and the average Lu-177 concentration in plasma increased to a maximum at 2 days postinfusion, followed by steady clearance. The residence time and RM doses were calculated for each radionuclide. In the current model, Re-188 was found to deliver the lowest RM dose, primarily because it had the shortest half-life, whereas Y-90 delivers the highest dose. Re-188 delivers 60% of the RM dose as compared with Lu-177 and can increase the dose to metastatic sites in the i.p. space by a similar factor. Based on limiting the RM dose to 200 cGy, the maximum administered activity of each radionuclide is as follows: (a) 106 mCi, Lu-177; (b) 58 mCi, I-131; (c) 34 mCi, Y-90; (d) 70 mCi, Re-186; (e) 169 mCi, Re-188; and (f) 110 mCi, Ho-166. Because of the delayed steady leakage of radiopharmaceuticals from the i.p. cavity to the plasma, short-lived radionuclides may offer special advantages for i.p. RIT.

Introduction

Bone marrow toxicity is the dose-limiting factor for i.p. RIT today. This toxicity is associated primarily with radioactivity that leaks from the i.p. cavity to the plasma and delivers a significant absorbed dose to the RM. Prudent selection of radionuclides for i.p. RIT could reduce the absorbed dose to the RM. The efficacy and toxicity of radionuclide therapy are usually interrelated, because the most desirable spatial and temporal patterns of energy delivered to targeted tumor cells are generally associated with enhanced toxicity. Selecting a suitable radionuclide requires careful consideration of many physical factors such as half-life, type/energy of particles/photons emitted, and availability, together with matching radiochemical properties. Results from modeling nine commonly available radionuclides for RIT indicated that Re-186 and Y-90 were the optimum candidates (1). In another report, based on time-dose fractionation and the linear-quadratic model, longer-lived radionuclides (P-32 and Y-91) were shown to offer superior therapeutic advantages compared with shorter-lived radionuclides such as Y-90 (2). More recently, proliferation of tumor cells and critical bone marrow tissues has been incorporated in these models, and the advantages of longer-lived radionuclides have been reiterated (3). In practice, longer-lived radionuclides are also limited because of the lower dose rate, and the amount of radionuclide bound to the carrier may be limited for longer-lived radionuclides.

Clinical RIT trials for ovarian cancer involve i.p. administration of radiopharmaceuticals to the i.p. space, where the radiolabeled antibodies bathe the surface of tumor deposits that are growing in the i.p. fluid and are attached to the surfaces of the i.p. wall. After i.p. administration of Lu-177 CC49 to 26 ovarian cancer patients, the concentration of radioactivity detected in blood increases steadily to reach a maximum at 2 days, followed by monoexponential clearance with a biological half-time of about 72 h (4). Similar results for i.p. therapy in patients have been reported for antibodies labeled with I-131 (5) and Re-186 (6). This leakage of radiopharmaceutical from the i.p. space to plasma in i.p. RIT interferes with the radionuclide selection criteria used for i.v. administration. Significant toxicity has been reported with i.p. RIT, and this report is concerned with exploiting the special advantages of shorter-lived radionuclides that will have decayed significantly by the time they move from the i.p. fluid to plasma.

Clinical trials with Lu-177-labeled CC49 i.p. therapy in ovarian cancer patients have established that the concentration of this radionuclide reaching plasma peaks at about 48 h postinfusion, followed by a steady clearance as the radioactivity is localized in various organs and excreted via the urine (6). Because the radioactivity exiting the i.p. space is considered to be the major contributor to bone marrow toxicity, choosing a radionuclide with a shorter half-life seems attractive. Ho-166, for example, has a half-life of 26.8 h and would have decayed by a factor of about 4 before it reached a maximum concentration in the plasma.

The objectives of this study were: (a) to compare RM doses for i.p. RIT with Lu-177, I-131, Y-90, Re-186, Re-188, and Ho-166, assuming they have in vivo pharmacokinetics identical to those of Lu-177 CC49; and (b) to predict the maximum activity (in mCi) of each radionuclide that can be administered without exceeding a dose of 200 cGy to the RM.

Materials and Methods

The model that describes the temporal distribution of i.p. infused radiopharmaceuticals in various compartments is shown in Fig. 1. The radiopharmaceutical is distributed throughout the
Fig. 2 Average uptake and clearance pattern of Lu-177 CC49 in plasma measured from 26 ovarian cancer patients. The PIA data for the five other radionuclides were calculated from the data measured for Lu-177.

Fig. 1 Qualitative schematic of assumed antibody kinetics used to derive radiation-absorbed doses to RM and whole body for i.p. RIT. At 7 days postinfusion, approximately 60% of radioactivity leaves the i.p. cavity and is localized in the remainder of the body or excreted.

The RM dose for each radiopharmaceutical was calculated from two sources of radioactivity: (a) plasma; and (b) the remainder of whole body. No specific uptake of the radiopharmaceutical or degradation products in the bone marrow or skeletal tissues was assumed for this model. The RT for bone marrow was calculated assuming the concentration of radionuclide in the RM was 0.19 of that in the plasma (8). Because S values for all of the radionuclides in this study were not available in MIRD11 S tables or the PC program MIRDose3, the source code for MIRDose2 was modified by Dow Chemical (Freeport, TX) with permission from Oak Ridge. This was used to provide RM dose estimates for the six radionuclides selected. Based on the results and setting the RM dose limit at 200 cGy, the maximum quantity of each radionuclide for i.p. therapy was calculated using

$$A_{\text{max}} = \frac{200}{\text{RM dose}}$$

where $$A_{\text{max}}$$ is the maximum administered activity (in mCi) of each radionuclide, and RM dose is the dose to the RM (in cGy/mCi) calculated for each of the radionuclides compared.

**Results**

This radionuclide selection model indicates the advantage of using shorter-lived radionuclides for i.p. RIT. The average radioactivity level detected in plasma from infusing 1 mCi of each radionuclide for i.p. RIT is depicted in Fig. 2. The concentration of the radionuclide in plasma is proportional to physical half-life of each radionuclide. The corresponding RTs for each radionuclide in plasma are depicted in Fig. 3. The half-life of each radionuclide represents the order of magnitude. The

---

4 MIRDose2, modified version supplied by Dr. Jim Simon (Dow Chemical Branch, Freeport, TX).
5 M. G. Stabin, Oak Ridge Institute for Science and Education, TN.
A Strategy to Reduce RM Dose for i.p. RIT

Table 1 Maximum administered activity predicted for i.p. RIT with each radionuclide attached to CC-49, based on limiting the RM dose to 200 cGy

<table>
<thead>
<tr>
<th>Radionuclide</th>
<th>Maximum activity predicted for i.p. RIT (mCi)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu-177</td>
<td>105</td>
</tr>
<tr>
<td>I-131</td>
<td>58.3</td>
</tr>
<tr>
<td>Y-90</td>
<td>34.1</td>
</tr>
<tr>
<td>Re-186</td>
<td>89.9</td>
</tr>
<tr>
<td>Re-188</td>
<td>170</td>
</tr>
<tr>
<td>Ho-166</td>
<td>110</td>
</tr>
</tbody>
</table>

Discussion

Although the goal for i.p. RIT is to restrict the radiolabeled antibody to the i.p. space, Anger camera images of every ovarian patient confirmed that a significant fraction of Lu-177 was outside the i.p. cavity. At 7 days postinfusion, approximately 60% of Lu-177 was estimated to be outside the i.p. cavity. Special techniques will be required to distinguish between the radioactivity localized in the liver from plasma-borne radioactivity and the radioactivity that is attached to the surface of this and other organs in the i.p. cavity.

The specific advantages offered by shorter-lived radionuclides for i.p. RIT cannot be assessed simply from a comparison of RT alone. Because the energy emitted from different radionuclides varies by a factor of 3 or more, the magnitude of RT alone does not provide the best estimate. Shorter-lived radionuclides usually also provide higher doses/dose rates to tumor volumes in the i.p. cavity, reduce RM doses from radioactivity that leaks out of the i.p. space into plasma, reduce exposure to hospital personnel, and may reduce the length of hospital stay for patients if the revised patient release criteria can be implemented.

These simplified modeling studies have indicated that Re-188 delivers the lowest RM dose for i.p. RIT, followed by Ho-166, Lu-177, I-131, Re-186, and Y-90. In theory, Re-188 could be supplied from a W-188 generator in therapy amounts, which would have a significant impact on the cost of i.p. RIT. The absorbed dose to tumor deposits in the i.p. cavity can be increased by a factor ≤ 3 for short-lived radionuclides that also emit longer range βs than Lu-177 and I-131, such as Re-188 and Ho-166. This approach is similar to methods described to estimate the bladder wall dose (9). Although there is some correlation between ranking the predicted amounts of I-131, Re-186, and Y-90 that have been administered for RIT, specific uptake of Y-90 in the skeletal tissues is likely to reduce the amount that can be administered for therapy.

Further refinement of the present model used to compare these six radionuclides for i.p. RIT should include doses to a tumor versus RM. Also, separating the contributions of dose from radioactivity in the i.p. space and the remainder of the body should provide more accurate estimates, because the photon contribution to total RM dose will be significantly lower than the values predicted, especially for low-energy photons emitted by Ho-166. If specific uptake of the radionuclide in the skeletal tissues could be visualized in Anger camera images (9), estimates of RM dose will be especially important, because this
contribution has been identified to have the strongest correlation with bone marrow toxicity (10).

References

A Strategy to Reduce Red Marrow Dose for Intraperitoneal Radioimmunotherapy

Daniel J. Macey and R. F. Meredith

* Clin Cancer Res * 1999;5:3044s-3047s.

Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/5/10/3044s

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.